Is Arrowhead Pharmaceuticals, Inc. (ARWR) a Buy, Sell, or Hold?
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$71.91 USD
-$2.2 (-2.97%)
- Volume
- 1.64M
- Average Volume
- 2.09M
- Market Capitalization
- $10.13B
- P/E Ratio
- -33.60
- Dividend Yield
- 0.00%
- Price Target
- $94.00
- Year High
- $87.83
- Year Low
- $14.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.23
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Christopher R. Anzalone |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ARWR |
| CUSIP | 04280A100 |
| CIK | 0000879407 |
| Web | https://arrowheadpharma.com |
| Phone | 626 304 3400 |
| Currency | USD |
| Employees | 711 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 2.24 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.23 |
| Quick Ratio | 6.23 |
| Cash Ratio | 0.64 |
Sales & Book Value
| Annual Sales | $829.45M |
| Price / Sales | 16.28 |
| Cash Flow | -0.36 |
| Price / Cash Flow | -199.11 |
| Price / Book | 16.68 |
Price Target and Rating
| Average Stock Price Forecast | $94.00 |
| High Stock Price Forecast | $100.00 |
| Low Stock Price Forecast | $46.00 |
| Forecast Upside/Downside | -23.50% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 21 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.0122 |
| Trailing P/E Ratio | -33.60 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-1.63M |
| Net Margin | -48.38% |
| Pretax Margin | -40.56% |
| Return on Equity | -55.45% |
| Return on Assets | -13.27% |
Financials Score
| AltmanZ Score | 3.54 |
| Piotroski Score | 3.00 |
| Working Capital | 1.54B |
| Total Assets | 2.27B |
| Ebit | -159.84M |
| Market Cap | 10.44B |
| Total Liabilities | 1.67B |
Poll Results
About Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead als ... o has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
2026-07-14 07:46:10
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
2026-06-29 16:42:09
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs Transcript
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
2026-06-25 08:15:12
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets.
2026-06-22 12:33:00
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Commission (EC) has formally granted marketing authorization for REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). REDEMPLO is the first and only siRNA medicine authorized by the EC for adults with FCS, diagnosed either by the presence of clinical crit.
2026-06-18 07:30:00
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule (TRiM™) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company's clinical candidates and externa.
2026-06-10 15:02:11
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction
2026-06-05 14:04:57
Arrowhead Pharmaceuticals NASDAQ: ARWR executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through its TRiM, or Targeted RNAi Molecule, platform.
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
2026-06-02 08:00:00
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global He
Frequently Asked Questions
-
What is the current Arrowhead Pharmaceuticals, Inc. (ARWR) stock price?
-
Arrowhead Pharmaceuticals, Inc.(NASDAQ:ARWR) stock price is $71.91 in the last trading session. During the trading session, ARWR stock reached the peak price of $87.83 while $14.3 was the lowest point it dropped to. The percentage change in ARWR stock occurred in the recent session was --2.97% while the dollar amount for the price change in ARWR stock was -$-2.2.
-
ARWR's industry and sector of operation?
-
The NASDAQ listed ARWR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARWR?
-
Mark Davis | Founder and Founder & Director of Insert Therapeutics Inc & Calando
Christopher R. Anzalone | Chairman, Chief Executive Officer & President
Daniel J. Apel | Chief Financial Officer
James C. Hamilton | Chief Medical Officer and Head of R&D
Vincent Anzalone | Head of Investor Relations & Vice President -
How many employees does ARWR have?
-
Number of ARWR employees currently stands at 711. ARWR operates from 177 East Colorado Boulevard, Pasadena, CA 91105, US.
-
Link for ARWR official website?
-
Official Website of ARWR is: https://arrowheadpharma.com
-
How do I contact ARWR?
-
ARWR could be contacted at phone #626 304 3400 and can also be accessed through its website. ARWR operates from 177 East Colorado Boulevard, Pasadena, CA 91105, US.
-
How many shares of ARWR are traded daily?
-
The average number of ARWR shares traded daily for last 3 months was 2.09M.
-
What is the market cap of ARWR currently?
-
The market value of ARWR currently stands at $10.13B with its latest stock price at $71.91